GW Pharmaceuticals PLC (GWPH.OQ)
14 Dec 2017
Wed, Dec 13 2017
* GW PHARMACEUTICALS REACQUIRES FULL RIGHTS TO DEVELOP AND COMMERCIALIZE SATIVEX® IN U.S.
BRIEF-GW Pharmaceuticals Announces Pricing Of Public Offering Of ADSs Raising Gross Proceeds Of $276 Million
* GW PHARMACEUTICALS PLC ANNOUNCES PRICING OF PUBLIC OFFERING OF ADSS RAISING GROSS PROCEEDS OF $276 MILLION
* GW PHARMACEUTICALS ANNOUNCES PROPOSED PUBLIC OFFERING OF ADSS
Zogenix Inc's experimental treatment for a rare form of epilepsy met the main goal in a late-stage study, the company said on Friday, more than doubling the value of its shares and hurting those of peer GW Pharmaceuticals .
* Analyst expects drug to become standard in Dravet treatment
* Gw Pharmaceuticals reports fiscal third quarter 2017 financial results and operational progress Source text for Eikon: Further company coverage:
- ROTY Edition 1 Volume 61: ASH Updates And Trades
- ROTY Edition 1 Volume 59: Updates And Trades
- GW Pharmaceuticals: A Desirable Mix Of Value And Catalysts
- GW Pharma Results Set Up A Key 2019
- Your Daily Pharma Scoop: Acadia Valuation, Galectin Plunges, Revance Positive Result
- ROTY Edition 1 Volume 58: Increasing Contender Coverage And Trades